Breakdown | |||||
TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
2.49M | 4.53M | 5.51M | 4.47M | 823.00K | 0.00 | Gross Profit |
1.57M | -29.24M | 4.62M | -15.54M | -13.62M | -1.35M | EBIT |
-41.48M | -40.89M | -36.95M | -23.82M | -21.59M | -19.75M | EBITDA |
-31.21M | -39.92M | -36.05M | -22.65M | -20.44M | -19.75M | Net Income Common Stockholders |
-41.36M | -69.05M | -36.89M | -23.22M | -22.82M | -19.02M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
13.52M | 13.52M | 14.85M | 10.29M | 9.65M | 6.03M | Total Assets |
109.96M | 98.36M | 95.83M | 69.77M | 39.52M | 25.45M | Total Debt |
120.37M | 120.37M | 48.81M | 37.99M | 13.15M | 2.86M | Net Debt |
106.85M | 106.85M | 33.96M | 27.70M | 3.50M | -3.17M | Total Liabilities |
142.03M | 130.43M | 59.75M | 44.37M | 20.66M | 10.86M | Stockholders Equity |
-32.06M | -32.06M | 36.08M | 25.40M | 18.86M | 14.59M |
Cash Flow | Free Cash Flow | ||||
-42.09M | -55.57M | -34.69M | -24.88M | -19.09M | -15.71M | Operating Cash Flow |
-37.73M | -47.42M | -32.48M | -23.57M | -18.27M | -15.58M | Investing Cash Flow |
-4.35M | -8.13M | -2.21M | -1.30M | -824.00K | 2.88M | Financing Cash Flow |
34.91M | 53.99M | 44.02M | 25.52M | 23.21M | 8.97M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
71 Outperform | $4.36B | 22.63 | 81.65% | ― | 63.39% | ― | |
51 Neutral | $533.88M | ― | 91.25% | ― | -17.75% | -19.17% | |
49 Neutral | $6.86B | 0.03 | -54.79% | 2.48% | 24.62% | -2.84% | |
44 Neutral | $70.56M | ― | 81.15% | ― | 34.92% | 30.59% | |
44 Neutral | $1.61B | ― | 18.68% | ― | 36.00% | 63.50% | |
44 Neutral | $13.12M | ― | 291.66% | ― | ― | ― |
Armata Pharmaceuticals announced positive results from its Phase 2 Tailwind study evaluating AP-PA02, an inhaled phage therapy for non-cystic fibrosis bronchiectasis patients with chronic Pseudomonas aeruginosa infections. The study demonstrated a statistically significant reduction in bacterial colony forming units, suggesting the potential of phage therapy to reduce reliance on chronic antibiotic use. AP-PA02 was well-tolerated with mild adverse events, highlighting its promising safety profile. These findings support Armata’s mission to develop phage-based therapeutics as new treatment alternatives for chronic pulmonary diseases.
Armata Pharmaceuticals has reached a separation agreement with its Chief Medical Officer, Dr. Mina Pastagia, effective November 13, 2024. Dr. Pastagia will receive her base salary for 12 months in exchange for releasing claims against the company, contingent on her compliance with the agreement terms.
The Company recently amended its Credit and Convertible Credit Agreements, extending their maturity dates to January 2026, a move that could impact its financial strategy. Concurrently, the Company announced the departure of its Chief Medical Officer, Mina Pastagia, offering her a severance package as they finalize her separation terms. These developments highlight significant operational and financial shifts for the Company.
Armata Pharmaceuticals has announced the full enrollment of its Phase 1b/2a diSArm study, evaluating the intravenous AP-SA02 as a potential treatment for Staphylococcus aureus bacteremia, a severe bloodstream infection. With results expected in early 2025, the study aims to address the growing resistance to antibiotics, offering hope for innovative bacteriophage therapies in combating challenging infections. The upcoming data could pave the way for a pivotal efficacy trial later in the year, marking a significant step in modern medicine’s fight against antibiotic-resistant pathogens.